AI-Driven Early Detection of Skin Cancer
About this study
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
- Condition
- Skin Cancer Melanoma
- Tested
- Smartphone-based AI skin lesion analysis (NuvanaDx platform).
- Sponsor
- Nuvana Healthcare LTD
Who can join
- Age
- 1.5 years and older
- Sex
- All sexes
- Healthy volunteers
- Accepted
Inclusion 4
- Minimum age: 1.5 years
- Study condition: Skin Cancer Melanoma
- Adults (≥18 years) presenting with skin lesions suspicious for malignancy.
- Ability to provide informed consent.
Exclusion 2
- Inability to provide informed consent.
- Poor-quality images unsuitable for AI analysis.
Where
1 site, 1 recruiting
Nuvana Healthcare Ltd
London, United Kingdom
Contact
-
Sushma Saxena, Director, Nuvana Healthcare Ltd
+44 7481986525 sushma.saxena@nuvana.co.uk
Potential match only. Final eligibility is determined by the study team.